The Problem of the Placebo Response in Clinical Trials for Psychiatric Disorders: Culprits, Possible Remedies, and a Novel Study Design Approach
The DOI matches its Crossref record; 33 of the 34 references it cites were found in a registry or an index.
Abstract
The placebo response is a major issue in clinical trials for psychiatric disorders. Possible contributing factors to this problem include diagnostic misclassification, issues concerning inclusion/exclusion criteria, outcome measures’ lack of sensitivity to change, measurement errors, poor quality of data entry and verification, waxing and waning of the natural course of illness, regression toward the mean phenomenon, patient and clinician expectations about the trial, study design issues, non-specific therapeutic effects, and high attrition. Over the past few decades, researchers have attempted to reduce the placebo effect in a variety of ways. Unfortunately, approaches with very little or no benefit have included restricting enrollment to selected populations, rater training, requirement of same rater, and placebo lead-in phases. Some benefits, although often marginal, have been derived from standardizing diagnostic procedures, managing clinicians’ overestimation of change, simplification of study visits and assessments, minimizing non-specific, therapeutic effects, extending trial duration, reducing number of sites, increasing the sensitivity of outcome measures, and reducing the number of treatment arms. Thus far, there has been no attempt to develop new study designs aimed at reducing the placebo effect. We are proposing a novel study design, called ‘Sequential Parallel Comparison Design’, suitable for double-blind, placebo-controlled trials in psychiatric disorders. This design is aimed at reducing both the overall placebo response rate and the sample size required for such trials. Its usefulness in clinical research needs to be tested empirically. If this study design were to be found to meet its stated goals, this could markedly facilitate the process of clinical development of new compounds for the treatment of psychiatric disorders.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Strategies to mitigate placebo response include increasing study duration, randomizing the run-in period, and addressing functional blinding in rapid-acting antidepressant trials [162]”
From Ketamine in neuropsychiatric disorders: an update (2024) · cites this paper as [162]
Citations
Cites
Linear Statistical Inference and its Applications: Second Editon
Rao, C. R. (1973) · Wiley Series in Probability and Statistics · doi:10.1002/9780470316436 · Cited by 10,489
A controlled trial of sustained-release bupropion, a nicotine patch, or both for smoking cessation
Jorenby, D. E., Leischow, S. J., Nides, M. A., Rennard, S. I., Johnston, J. A., Hughes, A. R., Smith, S. S., Muramoto, M. L., Daughton, D. M., Doan, K., et al. (1999) · New England Journal of Medicine · doi:10.1056/nejm199903043400903 · Cited by 1,585 · cited 1×
“These numbers are even more impressive as most negative trials are typically unpublished, suggesting that the average placebo response rate in MDD trials is probably closer to the 35–45p range.Similarly, in smoking cessation trials, the placebo response rate has progressively increased. For example, in a recent study…”
ResultIs the Placebo Powerless?: An Analysis of Clinical Trials Comparing Placebo with No Treatment
Hróbjartsson, A., & Gøtzsche, P. C. (2001) · New England Journal of Medicine · doi:10.1056/nejm200105243442106 · Cited by 1,503
Placebo Response in Studies of Major Depression: Variable, Substantial, and Growing
Walsh, B. T., Seidman, S. N., Sysko, R., & Gould, M. (2002) · JAMA · doi:10.1001/jama.287.14.1840 · Cited by 1,109
A Primer on Regression Artifacts
Campbell, D. T., & Kenny, D. A. (1999) · Medical Entomology and Zoology · Cited by 482
Hypericum Depression Trial Study Group (2002) · JAMA · doi:10.1001/jama.287.14.1807 · Cited by 480
Linear Statistical Inference and its Applications.
Moore, P. G., & Rao, C. R. (1967) · The Statistician · doi:10.2307/2987205 · Cited by 439
Rush, A. J., Carmody, T., & Reimitz, P. (2000) · International Journal of Methods in Psychiatric Research · doi:10.1002/mpr.79 · Cited by 427 · cited 1×
“Another useful approach is to use outcome measures that can be administered in both clinician- and patient-rated forms, as in the case of the Inventory of Depressive Symptomatology (IDS) [”
MethodThe Hamilton Depression Scale: EVALUATION OF OBJECTIVITY USING LOGISTIC MODELS
Bech, P., Allerup, P., Gram, L. F., Reisby, N., Rosenberg, R., Jacobsen, O., & Nagy, A. (1981) · Acta Psychiatrica Scandinavica · doi:10.1111/j.1600-0447.1981.tb00676.x · Cited by 425
Effectiveness of St John's Wort in Major Depression: A Randomized Controlled Trial
Shelton, R. C., Keller, M. B., Gelenberg, A., Dunner, D. L., Hirschfeld, R., Thase, M. E., Russell, J., Lydiard, R. B., Crits-Christoph, P., Gallop, R., et al. (2001) · JAMA · doi:10.1001/jama.285.15.1978 · Cited by 382
Research works printed but not linked: 2
- 10.1001/jama.271.24.1940 · doi:10.1001/jama.271.24.1940 · Paper page
- 10.1037//0022-006x.70.4.887 · doi:10.1037//0022-006x.70.4.887
Cited by
Items 401–460 of 460
N-Methyl-d-Aspartate (NMDA) Antagonists for the Treatment of Depression
Skolnick, P., Popik, P., & Trullás, R. (2010) · Birkhäuser Basel eBooks · doi:10.1007/978-3-0346-0241-9_1 · Cited by 2
“For example, among the 39 depression trials filed with the FDA as part of registration submissions in the 1990s, active drug was superior to placebo on all primary and secondary outcome measures less than 15% of the time [ 66 ].”
BackgroundResultClinical trials management at the site level
Kwentus, J. A. (2012) · Cambridge University Press eBooks · doi:10.1017/cbo9780511977640.010
El papel del placebo en ensayos clínicos en esquizofrenia
Sola, E. J., & Bernardo, M. (2013) · Psiquiatría Biológica · doi:10.1016/j.psiq.2013.09.006
The Placebo Effect and the Pharmaceutical Industry
Grant, L., & Roblin, D. (2005) · International Journal of Pharmaceutical Medicine · doi:10.2165/00124363-200519040-00003
“A useful review by Fava et al.[14] identified a number of possible culprits that may contribute to the placebo response seen in depression trials, and these can reasonably be applied to clinical trials in general.”
BackgroundMethodInfluentialPlacebo composition as tabula rasa in clinical trials
Apte, S. (2016) · International Journal of Pharmaceutical Excipients · doi:10.66617/001c.1116
Analysis Methods for a Sequential Parallel Comparison Design (SPCD)
Haber, H. E. (2015)
Brown, M. A., Bishnoi, R. J., Dholakia, S., & Velligan, D. I. (2015) · Expert Review of Clinical Pharmacology · doi:10.1586/17512433.2016.1135734
“ical trials is the sequential parallel comparison design [85].”
BackgroundSikora, M. (2015) · Deep Blue (University of Michigan)
Aarsland, D., Cummings, J. L., Weintraub, D., & Chaudhuri, К. R. (2013) · Cambridge University Press eBooks · doi:10.1017/cbo9781139856669.022
Bestimmung des Nutzens und des Zusatznutzens von Antiepileptika: eine kritische Übersicht
Schmidt, D., Surges, R., May, T. W., & Elger, C. E. (2015) · Aktuelle Neurologie · doi:10.1055/s-0035-1552653
Treatment of neuropsychiatric disturbances in Parkinson's disease: future prospects and strategies
Cummings, J. L., & Aarsland, D. (2013) · Cambridge University Press eBooks · doi:10.1017/cbo9781139856669.025
Placebo response in clinical trials: Taming the human brain
Yadav, R. K., & Bhardwaj, P. (2017) · International Journal of Clinical and Experimental Physiology · doi:10.4103/ijcep.ijcep_36_17
“to minimize placebo effect by introducing newer clinical trials designs, especially where psychological outcome(s) are being measured.[63] In addition, there have been suggestions”
BackgroundImplications of placebos and nocebos in clinical research
Colloca, L., & Haycock, N. R. (2018) · PNEI REVIEW · doi:10.3280/pnei2018-001009
Jung Yoon Heo, M., Jeon, H. J., D, M. F. M., Mischoulon, D., Baer, L., Clain, A. J., Doorley, J. D., Pisoni, A., & Papakostas, G. I. (2016) · The International Journal of Neuropsychopharmacology · doi:10.1093/ijnp/pyw043.153
Addressing High Placebo Response in Neuroscience Clinical Trials
Doros, G. D., Lim, P., & Liu, Y. (2018) · ICSA book series in statistics · doi:10.1007/978-981-10-7829-3_7
The Weight of a Term: "Substantial Evidence" and Buried Data
Justman, S. (2018) · Perspectives in biology and medicine · doi:10.1353/pbm.2018.0037
Methods for the Sequential Parallel Comparison Design
Silverman, R. K. (2017) · Carolina Digital Repository (University of North Carolina at Chapel Hill) · doi:10.17615/y43w-2g54
Auby, P. (2019) · Elsevier eBooks · doi:10.1016/b978-0-08-100616-0.00007-1
The issue of indiscriminative efficacy trials and placebo effects in paediatric psychopharmacology
Siegfried, K. (2019) · Elsevier eBooks · doi:10.1016/b978-0-08-100616-0.00009-5
Notes on power comparison between the sequential parallel comparison and other commonly-used designs
Lui, K. (2019) · Communications in Statistics - Simulation and Computation · doi:10.1080/03610918.2019.1682160
“Huang and Tamura (2010) studied efficiency between test procedures, including the linear combination test (Fava et al. 2003), Wald’s test, the score test and the likelihood-ratio test, under the SPCD. Baer and Ivanova (2013) provided a review of the situations in which the SPCD is preferable to the…”
BackgroundMethodResultInfluentialBenchmarking the effectiveness of community services for youth with anxiety disorders
Houlding, C. (2013) · Knowledge Commons (Lakehead University)
Holbrook, A. M., Goldsmith, C. H., & Leung, M. (2005) · Wiley eBooks · doi:10.1002/0470011815.b2a04037
Do Not Rule Out Double-blind Placebo Run-in Periods for Randomized Clinical Trials
Targum, S. D. (2022) · JAMA Psychiatry · doi:10.1001/jamapsychiatry.2022.0048
The analysis of a patient-reported outcome measure in on-demand medication data
Kessels, R. (2022) · Utrecht University Repository (Utrecht University) · doi:10.33540/1080
Holbrook, A. M., Goldsmith, C. H., & Leung, M. (2008) · Wiley eBooks · doi:10.1002/9780471462422.eoct984
Holbrook, A. M., Goldsmith, C. H., & Leung, M. (2014) · Wiley eBooks · doi:10.1002/9781118596005.ch61
Abstracts from the ASENT 14th Annual Meeting
(2011) · Neurotherapeutics · doi:10.1007/s13311-011-0044-2
“Biomarkers were considered to belong into one of four classes: those predicting (1) efficacy or (2) toxicity, or those enabling selection of (3) responsive subjects or (4) effective dosing regimens.”
BackgroundMethodImplications of Placebos and Nocebos in Clinical Research
Colloca, L., & Haycock, N. R. (2019) · Headache · doi:10.1007/978-3-030-02976-0_10
Holbrook, A. M., Goldsmith, C. H., & Leung, M. (2005) · Wiley eBooks · doi:10.1002/0471667196.ess7191
Fedorov, V. V., & Liu, T. (2014) · Wiley eBooks · doi:10.1002/9781118445112.stat07127
Erst die Evidenz prüfen – dann die Therapie empfehlen
Ujeyl, M., & Müller-Oerlinghausen, B. (2013) · Der Schmerz · doi:10.1007/s00482-013-1316-z
Clinical–ethical implications and applications
Benedetti, F. (2020) · Oxford University Press eBooks · doi:10.1093/oso/9780198843177.003.0017
Interventionsdesign, Evaluationsverfahren und Wirksamkeit von Interventionen
Reis, D., & Meier, L. L. (2022) · Springer eBooks · doi:10.1007/978-3-658-28651-4_24
Ozcan, G., Singh, M., & Mortensen, E. M. (2023) · Elsevier eBooks · doi:10.1016/b978-0-323-88423-5.00069-8
(2023) · Oxford University Press eBooks · doi:10.1093/med/9780197645444.002.0006
Taliaz, D., Lilian, R. R., Schurr, R., & Levin, L. (2023) · Medical Research Archives · doi:10.18103/mra.v11i10.4658
Marathakam, A., Mathew, V., & Unnikrishnan, M. K. (2024) · Frontiers in clinical drug research. CNS and neurological disorders · doi:10.2174/9789815179842124120004
SPCDAnalyze: Design and Analyze Studies using the Sequential Parallel Comparison Design
Schoenfeld, D. (2019) · doi:10.32614/cran.package.spcdanalyze
Self-citationChapter 66. Treatment of Autism Spectrum Disorder
Hegarty, J. P., & Hardan, A. Y. (2024) · American Psychiatric Association Publishing eBooks · doi:10.1176/appi.books.9781615375523.as66
Novel multi-modal methodology to investigate placebo response in major depressive disorder
Cusin, C., Dillon, D. G., Belleau, E. L., Normandin, M. D., Petibon, Y., El-Fakri, G., Dhaynaut, M., Hooker, J. M., Kaptchuk, T. J., McKee, M., et al. (2024) · Journal of Affective Disorders · doi:10.1016/j.jad.2024.08.226
“We use the sequential parallel comparison design (SPCD) (Fava et al., 2003) to maximize the number of placebo responders.”
BackgroundMethodInfluentialAdaptive promising zone design for sequential parallel comparison design with continuous outcomes
Lu, X., & Shan, G. (2025) · Clinical Trials · doi:10.1177/17407745241309056
Zaharia, S., & Horoșan, L. (2022) · Romanian Journal of Psychiatry & Psychotherapy · doi:10.37897/rjpp.2022.3-4.6
Okafor, C. N., Yoon, J. H., Jean-Berluche, D., Mayes, T. L., SHOPTAW, S. J., Trivedi, M. H., Potter, J. S., & Schmitz, J. M. (2025) · International Journal of Behavioral Medicine · doi:10.1007/s12529-025-10364-z
“The trial employed a sequential parallel comparison design (SPCD) [8] in which study participants were randomized in a 0.26:0.74 ratio during the first 6 weeks to receive NTX-BUP or placebo (stage 1).”
InfluentialUtilizing Win Ratio Approaches and Two-Stage Enrichment Designs for Small-Sized Clinical Trials
Wang, J., Chen, Y., & Gwise, T. E. (2025) · The New England Journal of Statistics in Data Science · doi:10.51387/25-nejsds85
Adaptive Sequential Parallel Comparison Designs with Treatment Selection for Continuous Outcomes
Wu, S. S., Ding, A. A., Yang, Y., DelRocco, N. J., & Shan, G. (2025) · Statistics in Biosciences · doi:10.1007/s12561-025-09490-9
“Chen et al. [6] proposed a weighted ordinary least squares test statistic for an SPCD with a continuous primary endpoint, and [10] developed a new SPCD for double-blind, placebo-controlled trials that reduces the placebo effect and sample size with applications to psychiatric disorders.”
Yang, Z. (2025) · Therapeutic Innovation & Regulatory Science · doi:10.1007/s43441-025-00881-0
“Alternative, more complex designs, such as the novel SPCD proposed by Fava et al. [18 ], could be explored.”
Stockton, B., Santacatterina, M., Mandal, S., Cleland, C. M., Hade, E. M., Illenberger, N., Meropol, S. B., Troxel, A. B., Petkova, E., Chang, Y., et al. (2025) · arXiv (Cornell University) · doi:10.48550/arxiv.2511.19677
“Placebo response complicates statistical inference and clinical understanding of treatment efficacy in placebo-controlled clinical trials in psychiatry and other fields[7, 1, 15].”
Cetamina no Tratamento da Perturbação de Stress Pós-Traumático em Veteranos de Guerra
Ribeiro, A. R. L. P. D. S. (2025) · Portuguese National Funding Agency for Science, Research and Technology (RCAAP Project by FCT)
Heinen, D. (2025) · publish.UP (University of Potsdam) · doi:10.25932/publishup-69124
Serretti, A. (2026) · International Clinical Psychopharmacology · doi:10.1097/yic.0000000000000614
Uchida, H., Gobbi, G., Zohar, J., Young, A. H., Rujescu, D., Huang, M.-C., Sundram, S., Atwoli, L., Vukovic, J., & Ikeda, K. (2026) · The International Journal of Neuropsychopharmacology · doi:10.1093/ijnp/pyag023
Moreira, M. F., & Oliveira, M. A. P. (2026) · Archives of Physical Medicine and Rehabilitation · doi:10.1016/j.apmr.2026.05.005
Sunzeri, F. (2026) · Springer eBooks · doi:10.1007/978-3-032-14465-2_16
Mojtabai, R., Susukida, R., Farokhnia, M., Nguyen, T. Q., Leggio, L., Bergeria, C. L., Prasad, S., Dunn, K. E., & Amin‐Esmaeili, M. (2026) · Journal of Psychopharmacology · doi:10.1177/02698811261464533
A two-stage design for evaluating induction and maintenance therapies for a time to event endpoint
Quan, H., Xu, Z., Zhang, R., Sarkar, S., & Qiu, C. (2026) · Contemporary Clinical Trials · doi:10.1016/j.cct.2026.108420
Douglas, C., Congdon, E. L., Huang, C., Seok, D., Cohen, Z. D., Akre, S., Tozzo, V., Huang, F., Ramo-Larios, D., Bernier, R. A., et al. (2026) · npj Digital Public Health · doi:10.1038/s44482-026-00029-3
“…initial improvement followed by stabilization of depression scores could be that individuals have a greater propensity to enroll in research studies during periods when symptoms are more severe, and that after enrollment the distribution of symptom severity follows a regression to the mean 40,41 .”
The Randomization Effect in a Double-Blind Placebo-Controlled Depression Study
Targum, S. D., Ceesay, P., Lines, C., Thase, M. E., Sanacora, G., & Merola, A. (2026) · Journal of Clinical Psychopharmacology · doi:10.1097/jcp.0000000000002250
Quan, H., Xu, Z., Qiu, C., & Chen, X. (2026) · Journal of Biopharmaceutical Statistics · doi:10.1080/10543406.2026.2728047
Psychiatric Comorbidity in Research on Medications for Opioid Use Disorder: A Systematic Review
Ameral, V., Falcón, A. K., Wolkowicz, N. R., Patterson, J. A., & MacLean, R. R. (2026) · The Journal of Nervous and Mental Disease · doi:10.1097/nmd.0000000000001883 · Cited by 1
Metadata
- Authors
- Fava, M., Evins, A. E., Dorer, D. J., & Schoenfeld, D. A.
- Affiliations
- Harvard University (US)
- Venue
- Psychotherapy and Psychosomatics
- Publisher
- S. Karger AG
- Published
- 2003
- Volume
- 72
- Issue
- 3
- Pages
- 115-127
- ISSN
- 0033-3190 (ISSN-L)
- 1423-0348
- OpenAlex
- W2073526412
- Cited by
- 452
- References
- 34
- Citations by year
- 2026: 15 · 2025: 22 · 2024: 17 · 2023: 18 · 2022: 21 · 2021: 16 · 2020: 29 · 2019: 41 · 2018: 23 · 2017: 32 · 2016: 21 · 2015: 29 · 2014: 22 · 2013: 21 · 2012: 22
- FWCI
- 5.72
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- www.karger.com/Services/SiteLicenses (vor)
- www.karger.com/Services/SiteLicenses (tdm)
- Locations
- Psychotherapy and Psychosomatics (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Life Sciences › Neuroscience › Cognitive Neuroscience › Pain Management and Placebo Effect
- Physical Sciences › Mathematics › Statistics and Probability › Statistical Methods in Clinical Trials
- Social Sciences › Psychology › Clinical Psychology › Psychotherapy Techniques and Applications
- Keywords
- placebo response, placebo effect, mental illness, clinical trial design, regression to the mean, attrition, sample size reduction, outcome measure sensitivity
- MeSH terms
- Mental Disorders, Clinical Trials as Topic, Double-Blind Method, Humans, Research Design, Reproducibility of Results, Placebo Effect
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.